Displaying drugs 12976 - 13000 of 15363 in total
RO-6870810
RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Matched Description: … clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and …
Duvortuxizumab
Duvortuxizumab is under investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma).
Investigational
Matched Description: … investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics, Pharmacodynamics, and …
Recombinant Super-Compound Interferon
Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.
Investigational
Matched Description: … This interferon has antiviral and antitumor activity. …
GED-0507-34-Levo
GED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged-0507-34-levo for Treatment of UC).
Investigational
Matched Description: … GED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged …
Epafipase
Epafipase is under investigation in clinical trial NCT00037687 (Safety and Efficacy of Recombinant Human Platelet-activating Factor Acetylhydrolase for the Treatment of Severe Sepsis).
Investigational
Matched Description: … Epafipase is under investigation in clinical trial NCT00037687 (Safety and Efficacy of Recombinant Human …
Tebotelimab
Tebotelimab is under investigation in clinical trial NCT04082364 (Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/gej Cancer (MAHOGANY)).
Investigational
Matched Description: … is under investigation in clinical trial NCT04082364 (Combination Margetuximab, INCMGA00012, MGD013, and …
OS2966
OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]
Investigational
Matched Description: … CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and …
F6-734
F6-734 is a bispecific monoclonal antibody with affinity for anticarcinoembryonic antigen (CEA) and anti-diethylenetriamine pentaacetic acid (DTPA) (hMN-14 × m734).[A255217,A255222]
Investigational
Matched Description: … F6-734 is a bispecific monoclonal antibody with affinity for anticarcinoembryonic antigen (CEA) and anti-diethylenetriamine …
HOV-12020
HOV-12020 is a palm tocotrienols complex being investigated for the treatment of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
Investigational
Matched Description: … investigated for the treatment of cerebral autosomal-dominant arteriopathy with subcortical infarcts and …
Povorcitinib
Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)).
Investigational
Matched Description: … Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety …
ANEB-001
ANEB-001 is under investigation in clinical trial NCT05282797 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test).
Investigational
Matched Description: … ANEB-001 is under investigation in clinical trial NCT05282797 (Safety, Tolerability, Pharmacokinetics, and …
Pulocimab
Pulocimab is under investigation in clinical trial NCT06341335 (A Study of Ak104/placebo Plus Ak109/placebo and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma).
Investigational
Matched Description: … Pulocimab is under investigation in clinical trial NCT06341335 (A Study of Ak104/placebo Plus Ak109/placebo and …
AS1409
AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours. It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and...
Investigational
Matched Description: … It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma …
KD3010
KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
Investigational
VTP-201227
VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications. It is being developed by Vitae Pharmaceuticals.
Investigational
Matched Description: … VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment …
ALKS 29
ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
Investigational
PF-03187207
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. The development of abnormally high IOP, due to blockage...
Investigational
Matched Description: … Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF- …
Norclozapine
ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
Investigational
Matched Description: … ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA …
LLL-3348
The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
Investigational
TG1024
Investigational
Manitimus
FK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in kidney transplant patients, potentially offering a breakthrough in immunosuppressive therapy.
Investigational
Matched Description: … FK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in …
RO-4584820
Investigational
Displaying drugs 12976 - 13000 of 15363 in total